Parra-Ortega I, López-Martínez B, Sánchez-Huerta JL, Vilchis-Ordóñez A, Barrera DL

Language: Spanish
References: 15
Page: 416-421
PDF size: 249.02 Kb.

ABSTRACT

Background. Epstein-Barr virus (EBV) viral load is useful not only for detection of an active infection but also as a tumor marker for certain malignant forms. In immunocompromised patients it is related to postransplant lymphoproliferative syndrome (PTLS) with an incidence on the order of 1 to 20%. It is recommended to determine viral load in whole blood and plasma to monitor patients at risk for developing PTLS. Real-time polymerase chain reaction (RT-PCR) is a useful tool for this determination. In these determinations the melting curve (Tm) plays an important role because changes in Tm suggest that the target sequence has suffered mutations, although the selected regions for detection and quantification of EBV are highly conserved. We undertook this study to describe the findings of the variations identified in the EBV genome and to perform the detection and quantification in samples of pediatric patients using RT-PCR.
Methods. Results from 352 pediatric patients were analyzed retrospectively in whom investigation of the EBV was performed in peripheral blood and plasma by RT-PCR. For detection and quantification of EBV, a 166-bp fragment of the genome was amplified using a design of TIB MOLBIOL and the LightCycler® equipment with a Tm of 68 °C.
Results. Of the 352 patients studied, in 132 (37.5%) presence of EBV was detected and quantified the viral load. In five (3.8%) of the positive patients, a change of the Tm was identified Using electrophoresis running in agarose gel, it was proved that the obtained amplification corresponds to the 166-bp fragment.
Conclusion. The specific product and size of the amplified remained unchanged; therefore, we there is a high probability of decrease in the concentration of guanine-cytosine in the target sequence because the Tm showed a decrease in all the reported cases. It is required the sequence of the amplification is required to precisely determine the cause of the decrease in the Tm.

REFERENCES

1. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. En: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. p. 2511.

2. Rickinson AB, Kieff E. Epstein-Barr virus. En: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. p. 2576.

3. Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol 2008;82:11217–11227.

4. Thorley-Lawson DA. Epstein-Barr virus: exploting the immune system. Nat Rev Immunol 2001;1:75-82.

5. Rickinson AB, Kieff E. Epstein-Barr virus and its replication. En: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds). Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp. 2594-2612.

6. Menet A, Speth C, Larcher C, Prodinger WM, Schwendinger MG, Chan P, et al. Epstein-Barr virus infection of human astrocyte cell lines. J Virol 1999;73:7722–7733.

7. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984;81:4510–4514.

8. Frade R, Barel M, Ehlin-Henriksson B, Klein G. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci USA 1985;82:1490–1493.

9. Haan KM, Lee SK, Longnecker R. Different functional domains in the cytoplasmic tail of glycoprotein B are involved in Epstein-Barr virus-induced membrane fusion. Virology 2001;290:106–114.

10. Haddad RS, Hutt-Fletcher LM. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J Virol 1989;63:4998–5005.

11. Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol 2007;81:7825–7832.

12. Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G, et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 2008;82:10175-10187.

13. Kogan DL, Burroughs M, Emre S, Fishbein T, Moscona A, Ramson C, et al. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients. Transplantation 1999;67:1068-1070.

14. Green M, Cacciarelli TV, Mazariegos GV, Sigurdsson L, Qu L, Rowe DT, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for postransplant lymphoproliferative disease. Transplantation 1998;66:1641-1644.

15. Patel S, Zuckerman M, Smith M. Real-time quantitative PCR of Epstein-Barr virus BZLF1 DNA using the LightCycler. J Virol Methods 2003;109:227-233.